Literature DB >> 1747046

Total axillary lymphadenectomy in the management of breast cancer.

G M Senofsky1, F L Moffat, K Davis, M M Masri, K C Clark, D S Robinson, B Sabates, A S Ketcham.   

Abstract

The optimal extent of axillary dissection in patients with breast cancer remains unclear. We report 278 total axillary lymphadenectomies (levels I, II, and III and Rotter's [interpectoral] nodes) that were performed in 264 closely followed up private patients. There have been no axillary recurrences to date (mean follow-up, 50 months). If only level I and II nodes had been removed, the false-negative staging error would have been only 2.6%. However, 29 (31.5%) of 92 pathological node-positive axillae contained apical and/or Rotter's metastases. The incidence of complications was comparable with that reported for partial lymphadenectomy. Arm lymphedema developed in 6% of nonirradiated patients; postoperative radiotherapy and gross nodal disease were significant risk factors for lymphedema. Total axillary lymphadenectomy largely prevents axillary, recurrence, eliminates the small staging error inherent in partial lymphadenectomy, and has acceptable morbidity, provided radiotherapy to the regional nodal areas is avoided.

Entities:  

Mesh:

Year:  1991        PMID: 1747046     DOI: 10.1001/archsurg.1991.01410350026004

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  17 in total

Review 1.  Axillary staging of breast cancer and the sentinel node.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

2.  Prognostic value of the interpectoral lymph nodes in breast cancer. A 20-year survival study.

Authors:  A García-Vilanova Comas; A García Vilanova; E Fuster-Diana; N Martínez-Alzamora; Jm Fernández-Tena; J García-Vilanova Comas; M García-Vilanova Comas
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

3.  Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients.

Authors:  Emin Yildirim; Ugur Berberoglu
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

4.  Intraoperative assessment of axillary lymph node metastases in operable breast cancer.

Authors:  M Noguchi; M Minami; M Earashi; T Taniya; I Miyazaki; Y Mizukami; A Nonomura
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5. 

Authors:  J C Rageth
Journal:  Arch Gynecol Obstet       Date:  1995-12       Impact factor: 2.344

6.  Risk factors associated with breast lymphedema.

Authors:  Judy C Boughey; Tanya L Hoskin; Andrea L Cheville; Joyce Miller; Margie D Loprinzi; Kristine M Thomsen; Shaun Maloney; Larry M Baddour; Amy C Degnim
Journal:  Ann Surg Oncol       Date:  2013-12-12       Impact factor: 5.344

Review 7.  Diagnosis of axillary lymph node metastases in patients with breast cancer.

Authors:  M Noguchi; N Katev; I Miyazaki
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  A prospective study of breast lymphedema: frequency, symptoms, and quality of life.

Authors:  Amy C Degnim; Joyce Miller; Tanya L Hoskin; Judy C Boughey; Margie Loprinzi; Kristine Thomsen; Shaun Maloney; Larry M Baddour; Andrea L Cheville
Journal:  Breast Cancer Res Treat       Date:  2012-03-14       Impact factor: 4.872

9.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer.

Authors:  A E Giuliano; D M Kirgan; J M Guenther; D L Morton
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

10.  Level III dissection in locally advanced breast cancer following neoadjuvant chemotherapy: a retrospective study.

Authors:  R V Bhargavan; A Mirza; K Cherian; J Krishna; P Augustine
Journal:  Ann R Coll Surg Engl       Date:  2019-11-22       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.